PDCD1LG2 and melanoma: This prognostic relevance was further validated in an independent cohort of melanoma patients treated with anti‐PD‐1 monotherapy, highlighting EV membrane PD‐L2 as a reliable biomarker of ICI‐based therapies in melanoma patients.